Royalty Pharma RPRX Price / sales
Price / sales at other companies
Other financials
Where this comes from
Calculated from Royalty Pharma’s reported figures.
Based on the most recent quarter.
The official record: Royalty Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Royalty Pharma's price / sales.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Royalty Pharma's price / sales?
- Royalty Pharma (RPRX) reported price / sales of 8.4× in Q1 2026.
- How has Royalty Pharma's price / sales changed year-over-year?
- Royalty Pharma's price / sales increased by 41.3% year-over-year, from 6× to 8.4×.
- What is the long-term trend for Royalty Pharma's price / sales?
- Over 4 years (2021 to 2025), Royalty Pharma's price / sales has grown at a -4.0% compound annual growth rate (CAGR), from 30.7× to 26×.
- What does price / sales mean?
- How many dollars investors pay for each dollar of the company's annual sales.
- How do you interpret price / sales?
- Useful when earnings are negative or volatile (e.g. early-stage or cyclical firms). Only comparable across companies with similar margins — a sales dollar is worth more at a high-margin business.
- How does price / sales compare across companies?
- Best compared within a margin cohort; a software P/S and a retailer P/S are not directly comparable.